167 related articles for article (PubMed ID: 35280770)
1. AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot Study.
Cao Z; Delfino K; Tiwari V; Wang X; Hannan A; Zaidi F; McClintock A; Robinson K; Zhu Y; Gao J; Cao D; Rao K
Front Oncol; 2022; 12():727505. PubMed ID: 35280770
[TBL] [Abstract][Full Text] [Related]
2. AKR1B10 overexpression in breast cancer: association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Ma J; Luo DX; Huang C; Shen Y; Bu Y; Markwell S; Gao J; Liu J; Zu X; Cao Z; Gao Z; Lu F; Liao DF; Cao D
Int J Cancer; 2012 Sep; 131(6):E862-71. PubMed ID: 22539036
[TBL] [Abstract][Full Text] [Related]
3. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
Ye X; Li C; Zu X; Lin M; Liu Q; Liu J; Xu G; Chen Z; Xu Y; Liu L; Luo D; Cao Z; Shi G; Feng Z; Deng H; Liao Q; Cai C; Liao DF; Wang J; Jin J; Cao D
Hepatology; 2019 Jun; 69(6):2489-2501. PubMed ID: 30672601
[TBL] [Abstract][Full Text] [Related]
4. Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
Han C; Gao L; Bai H; Dou X
Oncol Lett; 2018 Dec; 16(6):7123-7130. PubMed ID: 30546447
[TBL] [Abstract][Full Text] [Related]
5. Aldo-keto reductase 1B10 as a Carcinogenic but Not a Prognostic Factor in Colorectal Cancer.
Ye X; Wang T; Zhong L; Farrés J; Xia J; Zeng X; Cao D
J Cancer; 2024; 15(6):1657-1667. PubMed ID: 38370384
[TBL] [Abstract][Full Text] [Related]
6. Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma.
Wang Z; Kong L; Zhang R; Yang X; Cao Z; Xu T; Zhang H; Dou Y
J Hepatocell Carcinoma; 2024; 11():131-143. PubMed ID: 38250307
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 90-α mediates aldo-keto reductase 1B10 (AKR1B10) protein secretion through secretory lysosomes.
Luo D; Bu Y; Ma J; Rajput S; He Y; Cai G; Liao DF; Cao D
J Biol Chem; 2013 Dec; 288(51):36733-40. PubMed ID: 24217247
[TBL] [Abstract][Full Text] [Related]
8. AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Liu W; Song J; Du X; Zhou Y; Li Y; Li R; Lyu L; He Y; Hao J; Ben J; Wang W; Shi H; Wang Q
Acta Biomater; 2019 Jun; 91():195-208. PubMed ID: 31034948
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of aldo‑keto reductase family 1 member B10 in human nasopharyngeal carcinoma.
Lu J; Kang T; Zhang Z
Mol Clin Oncol; 2023 Nov; 19(5):89. PubMed ID: 37854325
[TBL] [Abstract][Full Text] [Related]
10. Impact of cytotoxic chemotherapy on aldo-keto reductase family 1 member B10 expression.
Robinson K; Cao Z; Delfino K; Cao D; Rao K
J Int Med Res; 2023 Jun; 51(6):3000605231179317. PubMed ID: 37389562
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
He YC; Shen Y; Cao Y; Tang FQ; Tian DF; Huang CF; Tao H; Zhou FL; Zhang B; Song L; He L; Lin LM; Lu FG; Liao DF; Cao D
Cancer Biomark; 2016; 16(1):127-35. PubMed ID: 26835713
[TBL] [Abstract][Full Text] [Related]
12. Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis.
Liu Y; Zhang J; Liu H; Guan G; Zhang T; Wang L; Qi X; Zheng H; Chen CC; Liu J; Cao D; Lu F; Chen X
Am J Cancer Res; 2019; 9(12):2730-2748. PubMed ID: 31911858
[TBL] [Abstract][Full Text] [Related]
13. Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-γ-dependent mechanism.
Matsunaga T; Suzuki A; Kezuka C; Okumura N; Iguchi K; Inoue I; Soda M; Endo S; El-Kabbani O; Hara A; Ikari A
Chem Biol Interact; 2016 Aug; 256():142-53. PubMed ID: 27417252
[TBL] [Abstract][Full Text] [Related]
14. AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.
Huang C; Cao Z; Ma J; Shen Y; Bu Y; Khoshaba R; Shi G; Huang D; Liao DF; Ji H; Jin J; Cao D
Mol Carcinog; 2018 Oct; 57(10):1300-1310. PubMed ID: 29846015
[TBL] [Abstract][Full Text] [Related]
15. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Han C; Gao L; Zhao L; Sheng Q; Zhang C; An Z; Xia T; Ding Y; Wang J; Bai H; Dou X
Med Sci Monit; 2018 Oct; 24():7414-7423. PubMed ID: 30328412
[TBL] [Abstract][Full Text] [Related]
17. AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-κB signaling pathway.
Qu J; Li J; Zhang Y; He R; Liu X; Gong K; Duan L; Luo W; Hu Z; Wang G; Xia C; Luo D
Cell Biosci; 2021 Aug; 11(1):163. PubMed ID: 34419144
[TBL] [Abstract][Full Text] [Related]
18. Role of AKR1B10 in inflammatory diseases.
Guo M; Wang T; Ge W; Ren C; Ko BC; Zeng X; Cao D
Scand J Immunol; 2024 May; ():e13390. PubMed ID: 38769661
[TBL] [Abstract][Full Text] [Related]
19. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
Li J; Guo Y; Duan L; Hu X; Zhang X; Hu J; Huang L; He R; Hu Z; Luo W; Tan T; Huang R; Liao D; Zhu YS; Luo DX
Oncotarget; 2017 May; 8(20):33694-33703. PubMed ID: 28402270
[TBL] [Abstract][Full Text] [Related]
20. Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.
Matsunaga T; Wada Y; Endo S; Soda M; El-Kabbani O; Hara A
Front Pharmacol; 2012; 3():5. PubMed ID: 22319498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
